Navigation Links
Hope for patients with HIV-associated cognitive impairment
Date:8/14/2012

Current drug therapy for patients with HIV is unable to control the complete replication of the virus in the brain. The drugs therefore do not have any effect against the complications associated with neurocognitive impairment in patients with HIV. New research by Joseph Steiner and colleagues from Johns Hopkins University has discovered that a group of plant polyphenols known as catechins, which naturally occur in green tea and the seed of the cacao tree, may help in the prevention of these neurological complications. Their work is published online in Springer's Journal of NeuroVirology.

Previous research has established the critical role of a protein called brain-derived neurotrophic factor (BDNF) in supporting the survival and growth of neurons in the brain. This protein is active in areas of the brain vital to learning, memory and higher thinking. Patients with HIV have been found to have lower levels of BDNF in their brains than healthy individuals suggesting that this could be directly responsible for the cognitive impairment suffered.

In their research, Steiner and colleagues analysed the effects of 2000 compounds, containing both natural substances and FDA-approved drugs, on brain cells in the laboratory. They identified a series of compounds which had the potential to help protect neurons in the brain. Nine of these were related to epicatechin, which is found in cocoa and green tea leaves. Further screening and comparison with resveratrol, the antioxidant found in red wine, specifically identified epicatechin and epigallocatechin gallate (EGCG) as being the most effective at helping protect neurons by inducing production of BDNF.

Although the antioxidant activities of epicatechin and EGCG are well documented, the discovery that they could be responsible for inducing production of BDNF is an exciting advancement in this area. The fact that these compounds readily cross the blood-brain barrier further increases their therapeutic potential, as this is often a major stumbling block in the development of therapies directed at the brain. This provides hope for patients with HIV as there is currently no neuroprotective therapy available for patients with HIV-associated cognitive impairment.

The authors conclude: "Due to its simpler structure and more efficient blood-brain barrier penetration properties, epicatechin might be the best therapeutic candidate for neurodegenerative diseases. These include HIV-associated cognitive disorders where oxidative stress is an important pathophysiological mechanism." Further research in patients with HIV is required to elucidate just how effective these naturally occurring compounds could be.


'/>"/>

Contact: Renate Bayaz
renate.bayaz@springer.com
49-622-148-78531
Springer
Source:Eurekalert

Related medicine news :

1. Study Questions Guidelines on Radiation for Older Breast Cancer Patients
2. Study: Majority of older, early-stage breast cancer patients benefit from radiation after lumpectomy
3. Individualized care best for lymphedema patients, MU researcher says
4. Rhode Island Hospital study: Bariatric patients with obstructive sleep apnea fail to show symptoms
5. Patients Often Kept in Dark About Off-Label Drug Use: Study
6. Underinsured Heart Disease Patients Die Sooner, Study Finds
7. Doctors often dont disclose all possible risks to patients before treatment
8. Patients want more risks disclosed before treatment
9. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
10. Weekends More Fatal for Older Patients With Head Injury: Study
11. Coach could be key in helping stroke patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: